Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.60 |
| ▸ | HTR2A | P28223 | 5/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | WEE1 | P30291 | 5/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069722 | 1.00 | HTR6 (0.60) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3566905 | 0.91 | HTR6 (0.59) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3566911 | 0.91 | HTR6 (0.59) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3561652 | 0.91 | HTR6 (0.61) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3561647 | 0.91 | HTR6 (0.61) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3565340 | 0.91 | HTR6 (0.73) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3557502 | 0.91 | HTR6 (0.73) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3568712 | 0.90 | HTR6 (0.60) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3568707 | 0.90 | HTR6 (0.60) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL2198003 | 0.90 | HTR6 (0.72) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | claimed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | claimed |
| CN-1315809-C | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2007-05-16 | — | — | CN | claimed |
| CN-1656075-A | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | CN | claimed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | claimed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | HTR6 111/4885HTR2A 124/4885HTR1A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.